IRRAS AB, a medical technology company focused on commercializing innovative solutions for neurocritical care, announced today it has acquired the assets of InnerSpace Neuro Solutions Inc. with immediate effect. These include proprietary single and multi-lumen cranial access bolts, parenchymal ICP (Intracranial Pressure) monitoring, and cranial access kit. The total purchase price for these assets, which are 510(K) FDA cleared in the United States but have not yet received CE Mark, was 700,000 USD.
The InnerSpace products have been used in over 2 000 patients, and their clinical utility is supported by a number of scientific publications. They complement IRRAS’ current IRRA flow product line and substantially expand the
company’s available product portfolio. Sales are expected to be initiated by the IRRAS’ US commercial organization in Q3 2019.
“This is a unique opportunity for IRRAS to strengthen its position and become a leader in the neurocritical care market. These innovative and proprietary products are a perfect fit to our product portfolio. In addition, we will use
established InnerSpace sales channels to introduce IRRA flow to new customers,” said Kleanthis G. Xanthopoulos, Ph.D., President & CEO.
There are clear and immediate commercial synergies that will provide IRRAS with innovative solutions across the treatment spectrum in neurocritical care.Furthermore, the acquired patents and expertise will result in accelerated
timeline and significantly reduced development costs of planned IRRA flow products.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Date: May 13, 2019
Source: Bloomberg